Aquatic Capital Management LLC Krystal Biotech, Inc. Transaction History

Aquatic Capital Management LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$108.01 - $179.35 $108,010 - $179,350	1,000 New	1,000 $177,000
Q3 2023 Nov 14, 2023	BUY	$108.51 - $130.22 $141,063 - $169,286	1,300 Added 1300.0%	1,400 $162,000
Q2 2023 Aug 14, 2023	SELL	$78.48 - $130.32 $62,784 - $104,256	-800 Reduced 88.89%	100 $12,000
Q1 2023 May 15, 2023	BUY	$72.39 - $84.27 $65,151 - $75,843	900 New	900 $72,000
Q2 2022 Aug 15, 2022	SELL	$48.93 - $73.47 $4,893 - $7,347	-100 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$51.99 - $72.11 $62,388 - $86,532	-1,200 Reduced 92.31%	100 $7,000
Q4 2021 Feb 14, 2022	BUY	$39.81 - $88.24 $51,753 - $114,712	1,300 New	1,300 $91,000

306

24.2M

483K

364K

Ticker KRYS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,664,300
Market Cap $3.97B
Description
Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...

Get notified when there are updates to the investment portfolio of Aquatic Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Aquatic Capital Management LLC with notifications on news.